9th Microbiome Movement Summit Europe
Maitrayee Chatterjee, Ph.D., Project Manager and Senior Scientist at InnoGI Technologies, discusses their innovative and non-invasive platform to mimic both the upper and lower gastrointestinal tract, offering precise and standardized…
Emil Chuang, Chief Medical Officer at Intrinsic Medicine, explores the growing understanding of gut-brain axis disorders and the potential of Human Milk Oligosaccharides (HMOs) in their treatment.
David Paez-Espino, Co-founder & CTO at Ancilia Biosciences, discusses the use of CRISPR technology to develop a new class of bacterial therapies that address critical gaps in microbiome-based treatments.
Chris Ford, Senior Vice President, Translational Biology at Seres Therapeutics, discusses the development of SER-155, a cultivated bacterial consortium designed to address the unmet medical need of preventing bloodstream infections…
Celine Druart, from the Pharmabiotic Research Institute, highlighted critical challenges in the microbiome field, particularly around the standardization of clinical protocols and analytical methods.
Nigel Titford, CEO at Biogaia Pharma, discusses the strategic considerations and challenges involved in working across both the dietary supplement and pharmaceutical sectors.
